-
Sichuan pharmaceutical company will win over $10 billion in anticoagulant apixaban tablets
Time of Update: 2022-03-06
0 China Drug Evaluation Database In terms of antithrombotic drugs, Chengdu Baiyu Pharmaceutical submitted 3 generic drug marketing applications under new classifications, among which rivaroxaban tablets have been approved for production and are deemed to have been reviewed, and apixaban tablets are expected to become the company's second approved drug Reviewed antithrombotic drugs .
-
Key data of Livzon Pharma's phase III clinical trial of recombinant novel coronavirus fusion protein vaccine sequential strengthening
Time of Update: 2022-03-06
issued an announcement stating that the "recombinant novel coronavirus fusion protein vaccine" ("V- 01”) has completed the interim master data analysis of the Sequentially Strengthened Phase III clinical trial, and obtained key data .
-
The Dendrobium officinale industry broke out and Tiefengtang was approved as the first food and drug quality management pilot enterprise in Zhejiang Province
Time of Update: 2022-03-03
The Dendrobium officinale industry broke out and Tiefengtang was approved as the first food and drug quality management pilot enterprise in Zhejiang Province
-
ADC: The "Magic Bullet" Road to Innovation
Time of Update: 2022-03-03
The initial inspiration for ADC antibody-drug conjugates came from the magic bullet idea proposed by Nobel Prize winner Paul Ehrlich: according to the special structural characteristics of pathogens, drugs that only kill pathogens and do not affect normal tissues and cells can be found and developed, and if chemotherapeutic drugs are used Attached to an antibody, the selectivity and efficacy of the treatment can be improved .
-
Lukang's entry skyrocketed by 180%, and the market of 5 billion urinary system drugs made waves again
Time of Update: 2022-03-02
Source: One-click retrieval from Minet At present, 8 companies have production approval documents for dapoxetine hydrochloride tablets.
Source: One-click retrieval from Minet At present, 8 companies have production approval documents for dapoxetine hydrochloride tablets.
-
Zai Lab's Phase 3 pivotal clinical study PANOVA-3 completes the first patient enrollment in Greater China
Time of Update: 2022-02-22
Recently, Zai Lab announced that PANOVA-3, a pivotal Phase 3 clinical study of tumor electric field therapy for pancreatic cancer, completed the first patient enrollment in Greater China .
-
Early-stage use of enoxaparin in COVID-19 improves clinical symptoms and reduces hospital stays
Time of Update: 2022-02-22
According to preliminary data of the study, timely use of enoxaparin at higher than preventive doses or moderate doses of new coronary pneumonia patients can shorten the hospital stay by 20% or more and relieve symptoms in more than 65% of cases .
-
CNS breakthrough!
Time of Update: 2022-02-22
S. FDA approved the international Phase IIb clinical trial of Soyuan Bio’s first-in-class drug DB104 (liafensine) against refractory depression (TRD).
Suoyuan Bio will initiate this international Phase IIb clinical trial based on FDA approval to evaluate the safety and efficacy of DB104 in TRD patients .
-
Hengrui Medicine Nimodipine Oral Liquid is about to be approved and is expected to win the first domestic imitation
Time of Update: 2022-02-21
A few days ago, the official website of the State Food and Drug Administration showed that Jiangsu Hengrui Pharmaceutical's nimodipine oral liquid entered the administrative approval stage as a 3-type imitation, and is expected to win the first domestic imitation .
-
GEMSTONE-302 study of sugalimab injection in first-line treatment of metastatic non-small cell lung cancer reaches the study endpoint of overall survival
Time of Update: 2022-02-19
Based on the excellent progression-free survival (PFS) data previously reported in the GEMSTONE-302 study, the National Medical Products Administration (NMPA) of China has approved the New Drug Application (NDA) of Zejimet® for combination chemotherapy in December 2021 First-line treatment of patients with metastatic squamous and non-squamous NSCLC .
-
The 5th domestic Ruckus Pharma capecitabine tablet was approved for production and deemed to have been reviewed
Time of Update: 2022-02-19
Sales of oral antineoplastic drugs in physical pharmacies in cities in China (unit: ten thousand yuan) Source: Competitive landscape of physical pharmacy terminals in Chinese cities In recent years, the sales scale of oral anti -tumor drugs in physical pharmacy terminals in urban China has continued to expand, and the sales growth rate has remained at double digits.
-
Innovative drugs: Please pay attention to the ICH-E series to obtain an implied clinical license
Time of Update: 2022-02-19
Completed by: Checking whether the information obtained by the sponsor during the reporting period is consistent with the original safety information of the investigational drug; Describing new safety issues that may affect the protection of clinical trial subjects; Recognition and management of identified and potential risks; updates on clinical research/development program status and findings .
-
Xianweida Announces Initiation of Patient Dosing in the International Multicenter IIb Clinical Trial of Its GLP-1 Drug Candidate XW003 in Obesity
Time of Update: 2022-02-17
, a clinical-stage biotechnology company focused on researching and developing innovative treatments for chronic metabolic diseases, announced today that the Phase IIb clinical trial of XW003 for the treatment of obesity has initiated patient dosing .
-
The research results of Hengrui Medicine's innovative drugs in the treatment of brain metastases from breast cancer are listed in "The Lancet. Oncology"
Time of Update: 2022-02-17
On January 25, the research results of pyrotinib combined with capecitabine in the treatment of HER2-positive breast cancer brain metastases led by Professor Yan Min from Henan Cancer Hospital were officially published online in the international authoritative medical journal "The Lancet.
-
Lingke Pharma Announces New Progress in Phase II Clinical Study of Ankylosing Spondylitis
Time of Update: 2022-02-17
The company today announced that the first patient has been dosed in a Phase II clinical trial of its selective JAK1 inhibitor LNK01001 for the treatment of autoimmune diseases in Ankylosing Spondylitis (AS) .
-
China Renaissance Capital 2021 Annual Review of the Medical and Life Technology Industry｜Diagnosis and Life Sciences
Time of Update: 2022-02-17
2021 is the second year that we are coexisting with the new crown epidemic. New changes and opportunities are constantly emerging in the field of medical and health care: frequent capital market poli
-
CStone Pharmaceuticals Announces Completion of Subject Enrollment in Two Phase III Registration Clinical Trials of Zejimet(R) (Sugelimab Injection)
Time of Update: 2022-02-16
The GEMSTONE-304 study is a multicenter, placebo-controlled, Phase 3 registrational clinical trial evaluating ZEJME® in combination with FP chemotherapy (fluorouracil + cisplatin) as first-line treatment for unresectable locally advanced, recurrent or metastatic disease The Phase Ib study on the efficacy and safety of esophageal squamous cell carcinoma showed that the objective response rate of Zejimei® combined with FP chemotherapy as first-line treatment of advanced esophageal squamous cell carcinoma reached 67.
-
"AI Pharma"--a game-breaker who broke the involution of innovative drug R&D?
Time of Update: 2022-02-16
Insilicon is an AI drug developer that uses end-to-end artificial intelligence to identify targets, generate new molecules (Generative Chemistry) and synthetic biology data (Generative Biology), and predict clinical trial outcomes .
-
Yangzijiang enters the bureau with 600 million antithrombotic injections, and the original research drug is hit again
Time of Update: 2022-01-27
Note: The original text has been deleted Source: CDE official website, Minet database A few days ago, the CDE official website showed that the argatroban injection of Yangzijiang Pharmaceutical Group Guangzhou Hairui Pharmaceutical was accepted as a 4-type imitation .
-
Shandong's new era of new drugs broke out!
Time of Update: 2022-01-26
Table 1: New drugs declared for clinical trials by Shandong New Era Pharmaceuticals since 2021 Source: CDE official website According to data from Minet.
Table 1: New drugs declared for clinical trials by Shandong New Era Pharmaceuticals since 2021 Source: CDE official website According to data from Minet.
